The add-on design was frequently used in registration studies. For infliximab, etanercept, adalimumab and rituximab, add-on trials contributed, together with parallel-group trials, to gaining the approval as combination therapy. Anakinra and abatacept were authorised on the basis of add-on trial ...
Finally, although mechanism of acupuncture’s effect on FD has been studied, therapeutic mechanism of moxibustion has not been studied and is subjected to further research. Conclusion With clinical evidence summarized by this overview of SRs and NMA, it is observed that the combination of manual ...
Thyroid incidentalomas have created a clinical ... HC Diener,R Sacco,S Yusuf - 《Cerebrovascular Diseases》 被引量: 248发表: 2007年 Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-... ...
Studies were retained if (1) SSRI add-on therapy was compared with antipsychotic monotherapy among schizophrenia-spectrum disorder patients; (2) the clinical trial was randomized, double-blind, placebo-controlled with parallel-arm design; (3) negative symptoms were assessed with the Scale for the ...
Methods/design This is a multicenter randomized controlled add-on superiority trial that enrolls patients attending sexual assault centers within 72 h after rape or attempted rape. The objective is to assess whether mPE shortly after rape can prevent the development of post-traumatic stress symptoms....
Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patient... the investigator, based on each patient's clinical status and the determination of the investigator that the patient may receive clinical ben...
Design, Setting, and Participants This double-blind, placebo-controlled randomized clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018; follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in Australia, Poland, Spain, the Netherl...
Methods Design Randomized controlled trial (Assess... OL Morey-Vargas,P Shah - 《Annals of Internal Medicine》 被引量: 0发表: 2014年 GLP1- RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Adding glucagon-like peptide-1 receptor agonists ( ...
In summary, DAWN showed that using dorzagliatin as an add-on to metformin can provide effective glycemic control with a good tolerability and safety profile in patients with T2D who had inadequate control with metformin alone. Methods Trial design ...
Alongside this trial-and-error approach, some medical directors draw on their clinical experiences to suggest that certain treatments may only work for a subsection of patients and may therefore be beneficial even if their efficacy is not clear in studies drawing on larger populations: So, I think...